Cystic Fibrosis Foundation (CFF) grants will help fund four programs that support the well-being of people with cystic…
Articles by Steve Bryson, PhD
CFTR correctors, such as elexacaftor, a component of the cystic fibrosis (CF) therapy Trikafta, may improve lung function…
The diversity and composition of bacteria in the gut of adults with cystic fibrosis (CF) differed significantly from that…
Biofilms of Pseudomonas aeruginosa visualized directly in sputum (phlegm) samples collected from children with cystic fibrosis (CF) did…
Two non-invasive tests — MRI scans and the lung clearance index (LCI) — were more sensitive to early lung…
A woman and her daughter were diagnosed with chronic rhinosinusitis, an inflammatory condition of the sinuses and nasal passages, with…
One year of Trikafta treatment improved lung function, reduced abnormalities in lung structure, and halted disease progression among school-age…
Using a newly enhanced gene-editing technology called prime editing, researchers in the U.S. have efficiently corrected the most common mutation…
Arcturus Therapeutics plans to soon submit an application to the U.S. Food and Drug Administration (FDA) seeking permission…
Among young children with cystic fibrosis (CF), starting the approved oral therapy Orkambi (ivacaftor/lumacaftor) led to favorable changes…